Crinetics
CRNX · NASDAQ
Bulios Fair Price
$51.68
39.2% downside
Current Price
$84.95
According to Bulios Fair Price, CRNX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Crinetics Pharmaceuticals, Inc. is a biotechnology company focused on developing therapeutics for the treatment of endocrine and metabolic disorders. The company specializes in discovering and developing new drugs that modulate G-protein-coupled receptors, which are key mechanisms for regulating hormonal signaling in the body. Crinetics focuses on developing treatments for diseases such as acromegaly (caused by excessive growth hormone secretion), Cushing’s disease, and other hormonal disorders. The company's goal is to provide innovative treatment options for patients with these rare conditions.
Sector
Healthcare
Industry
Biotechnology
CEO
R. Scott Struthers
Employees
594
Headquarters
San Diego
Upcoming events
Earnings
Upcoming earnings report